HC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $15 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Matthew Caufield has reiterated a 'Buy' rating on Aldeyra Therapeutics (NASDAQ:ALDX) and maintained a $15 price target.
June 30, 2023 | 10:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aldeyra Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $15.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Aldeyra Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100